Clinical Diabetes: Winter 2013 Nearly 12% of all Hispanics have diabetes, compared to 7.1% of non-Hispanic whites. The prevalence of diagnosed diabetes is not homogenous within subgroups of the Hispanic population, but instead ranges from as low as 7.6% for Cubans to as high as 13.3 and 13.8% for Puerto Rican and Mexican Americans, respectively.1 Disparities in […]
Diabetes Care: February 2013 OBJECTIVE To characterize middle-school students from the HEALTHY study with glycemic abnormalities, specifically high-risk hemoglobin A1c (A1C) (hrA1C; A1C = 5.7–6.4%) and impaired fasting glucose (IFG; fasting plasma glucose [FPG] = 100–125 mg/dL). RESEARCH DESIGN AND METHODS History was collected by self-report, physical measurement was collected by trained study staff, and fasting blood was drawn […]
Diabetes Care: January 28, 2013 OBJECTIVE To study the association of depressive symptoms or antidepressant medicine (ADM) use with subsequent cardiovascular disease (CVD) risk factor status in the Look AHEAD (Action for Health in Diabetes) trial of weight loss in type 2 diabetes. RESEARCH DESIGN AND METHODS Participants (n = 5,145; age [mean ± SD] 58.7 ± 6.8 years; […]
Diabetes Care: January 28, 2013 OBJECTIVE Macronutrient “preloads” can reduce postprandial glycemia by slowing gastric emptying and stimulating glucagon-like peptide-1 (GLP-1) secretion. An ideal preload would entail minimal additional energy intake and might be optimized by concurrent inhibition of dipeptidyl peptidase-4 (DPP-4). We evaluated the effects of a low-energy D-xylose preload, with or without sitagliptin, on gastric emptying, […]
FDA: Jan. 25, 2013 The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets. Alogliptin is a new active ingredient, while […]
Clinical Diabetes: Winter 2013 Objective. Dipeptidyl peptidase-4 (DPP-4) inhibitors decrease degradation of the incretins and peptides such as substance P that may be involved in the pathogenesis of ACE inhibitor–associated angioedema. This study sought to determine the effect of DPP-4 inhibition on patients’ risk of developing clinical angioedema. Design. The authors compared the incidence of angioedema in patients […]
Metabolism Journal: 8/12/12 Objectives Women with type 2 diabetes (T2D) show greater rates of mortality due to ischemic heart disease than men with T2D. We aimed to examine cardiovascular and autonomic function responses to isometric handgrip (IHG) exercise between men and women with T2D, before and after an exercise training program. Materials/Methods Hemodynamic responses were measured […]
Diabetes Care: February 2013 In the past decades, the sophistication of treatments for diabetes has increased dramatically, and evidence for effective interventions has proliferated. As a result, it is now possible to achieve excellent glucose control and reduce the risk of many of the complications associated with the disease. Despite these advances, however, many people with […]
JASN: January 29, 2013 Type 2 diabetes associates with increased risk of mortality, but how kidney disease contributes to this mortality risk among individuals with type 2 diabetes is not completely understood. Here, we examined 10-year cumulative mortality by diabetes and kidney disease status for 15,046 participants in the Third National Health and Nutrition Examination […]
Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents Pediatrics: January 28, 2013 Over the past 3 decades, the prevalence of childhood obesity has increased dramatically in North America, ushering in a variety of health problems, including type 2 diabetes mellitus (T2DM), which previously was not typically seen until much later in […]
 |
